Bright Machines offers free automation service to develop medical devices
Category: #health  By Pankaj Singh  Date: 2020-03-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bright Machines offers free automation service to develop medical devices

As the world comes together to fight against the deadly COVID-19 virus, more and more organizations are pledging their support to find a treatment for this novel disease. Recently, Bright Machines, a smart manufacturing firm, made a similar move when it announced its latest initiative to eradicate the issue of medical product shortages amidst the COVID-19 pandemic.

Reportedly, Bright Machines is planning to offer one-year, no-cost automation for manufacturing devices that are essential for devising a treatment for coronavirus. After evaluating all the recent drug development measures, it has now become clear that both an adequate supply of treatment resources, particularly respirators & ventilators, and access to testing is crucial for effective drug development.

To help simplify the issue of making essential medical devices readily available, Bright Machines would offer no-cost access for nearly 12 months on any of its Microfactory deployment that is linked with the COVID-19 response.

These Microfactories would help drug developers to quickly scale up their production by employing modular automation that is less dependent on human operators as to traditional inspection and assembly processes.

Evidently, Bright Machines Select is the firm’s microfactory-as-a-service model, that offers all the advantages of Software-Defined Manufacturing to drug developers without the downside of enduring traditional automation equipment’s associated upfront costs.

For the record, Bright Machines possesses deep experience in the automation space, and had recently joined hands with Diagnostics for the Real World (DRW) to automate the manufacturing of DRW’s pioneering SAMBA testing and diagnostic platform.

Elaborating about the benefits of Bright Machines Select, the model simplifies the process of budgeting, contracts, and financial evaluation for manufacturers. Moreover, the platform eliminates friction and optimizes the purchasing process for drug developers that are eyeing to deploy smart automation to enhance their lines.

Speaking on Bright Machine Select, Amar Hanspal, CEO, Bright Machines, said that the company has the vision to democratize the way products get manufactured so that people can attain products made using cost-effective & efficient production techniques at remote locations.

Source Credit: https://finance.yahoo.com/news/bright-machines-moves-scale-medical-150000000.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Appili gets FDA approval to expand the clinical trial of favipiravir
Appili gets FDA approval to expand the clinical trial of favipiravir
By Pankaj Singh

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application ...

Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
By Pankaj Singh

The Ministry of Health, Saudi Arabia, has reportedly announced that it will begin the third phase of clinical trials for a COVID-19 vaccine, as part of its cooperation with China’s CanSino Biologics Inc. The tria...

Amazon cleared by UK regulators to buy 16% stake in Deliveroo
Amazon cleared by UK regulators to buy 16% stake in Deliveroo
By Pankaj Singh

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to ...